Abstract
BACKGROUND Left-right asymmetry is an important organizing feature of the healthy brain that may be altered in schizophrenia, but most studies have used relatively small samples and heterogeneous approaches, resulting in equivocal findings. We carried out the largest case-control study of structural brain asymmetries in schizophrenia (N = 11,095), using a single image analysis protocol.
METHODS We included T1-weighted data from 46 datasets (5,080 affected individuals and 6,015 controls) from the ENIGMA Consortium. Asymmetry indexes were calculated for global and regional cortical thickness, surface area, and subcortical volume measures. Differences of asymmetry were calculated between affected individuals and controls per dataset, and effect sizes were meta-analyzed across datasets. Analyses were also performed with respect to the use of antipsychotic medication and other clinical variables, as well as age and sex. Case-control differences in a multivariate context were assessed in a subset of the data (N = 2,029).
RESULTS Small average differences between cases and controls were observed for asymmetries in cortical thickness, specifically of the rostral anterior cingulate (d = -0.08, pFDR = 0.047) and the middle temporal gyrus (d = -0.07, pFDR = 0.048), both driven primarily by thinner cortices in the left hemisphere in schizophrenia. These asymmetries were not significantly associated with the use of antipsychotic medication or other clinical variables. Older individuals with schizophrenia showed a stronger average leftward asymmetry of pallidum volume than older controls (d = 0.08, pFDR = 9.0 × 10-3). The multivariate analysis revealed that 7% of the variance across all structural asymmetries was explained by case-control status (F = 1.87, p = 1.25 × 10-5).
CONCLUSIONS Altered trajectories of asymmetrical brain development and/or lifespan asymmetry may contribute to schizophrenia pathophysiology. Small case-control differences of brain macro-structural asymmetry may manifest due to more substantial differences at the molecular, cytoarchitectonic or circuit levels, with functional relevance for lateralized cognitive processes.
Competing Interest Statement
O.A.A. is a consultant to HealthLytix. J.B. has received royalties from UpToDate. D.H.M. is a consultant for Recognify Life Sciences Inc., and Syndesi Therapeutics. A.B. received consulting fees by Biogen and lecture fees by Otsuka, Janssen, and Lundbeck. C.M.D-C. has received honoraria from Exeltis and Sanofi. C.Ar. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. S.K. receives royalties for cognitive test and training software from Schuhfried, Austria. B.F. has received educational speaking fees from Medice GmbH.
Funding Statement
The ENIGMA project is in part supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health (NIH) (Grant No. U54EB020403). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. D.S., M.C.P., S.E.F. and C.F. [ENIGMA-Laterality] were funded by the Max Planck Society (Germany). R.A-A. [PAFIP] is funded by a Miguel Servet contract from the Carlos III Health Institute (CP18/00003). J.V-B. [PAFIP] has received unrestricted research funding from Instituto de Investigación sanitaria Valdecilla (IDIVAL): INT/A21/10, INT/A20/04. D.A. [TOP] is funded by the South-Eastern Norway Regional Health Authority (grants 2019107 and 2020086). L.T.W. [TOP] is funded by The Research Council of Norway (223273, 300767), the South-Eastern Norway Regional Health Authority (2019101), and the European Research Council under the European Union's Horizon 2020 research and Innovation program (ERC StG, Grant 802998). O.A.A. [TOP] is funded by the Research Council of Norway (#223273, #275054) and KG Jebsen Stiftelsen, South East Norway Health Authority (2017-112, 2019-108). P.K. [MPRC, Huilong] received support from NIH grants R01MH123163 and R01EB015611. M.J.G. [ASRB, IGP] received funding from NHMRC Project Grants 630471, 1051672, 1081603. C.P. [ASRB] was supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1105825), and NHMRC L3 Investigator Grant (1196508). V.D.C. [FBIRN, COBRE] was funded by NIH grants R01MH118695 and NSF 2112455. J.M.F. [FBIRN] was funded by a Senior Research Career Scientist Award, Department of Veterans Affairs. P.F-C. [FIDMAG] is funded by CIBERSAM and by Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, 'Investing in your future'): Sara Borrell Research contract (CD19/00149). G.S. [RomeSL] was funded by Italian Ministry of Health RC17-18-19-20-21/A grants. A.N.V. [CAMH] currently receives funding from the National Institute of Mental Health, Canadian Institutes of Health Research, Canada Foundation for Innovation, CAMH Foundation, and the University of Toronto. K.S. [IMH] received support from research grants from the National Healthcare Group, Singapore (SIG/05004; SIG/05028), and the Singapore Bioimaging Consortium (RP C009/2006). Y-C.C. [JBNU] was supported by a grant of the Korean Mental Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HL19C0015) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI18C2383). U.D. [FOR2107 Münster] was funded by the German Research Foundation (DFG, grant FOR2107 DA1151/5-1 and DA1151/5-2; SFB-TRR58, Projects C09 and Z02) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Münster (grant Dan3/012/17). J.M.S. [COBRE] was funded by NIH grant 1P20RR021938-01. A.R.M. [COBRE] received funding from NIH grants P30GM122734 and R01MH101512. C.M.D-C. [Madrid] has received funding from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI17/00481, PI20/00721, JR19/00024). S.Ce. [KaSP] received funding from the Swedish Research Council (Grant No. 523-2014-3467). M.Kir. [Zurich] acknowledges funding from the Swiss National Science Foundation (P2SKP3_178175). T.H. [ESO] was supported by funding from the Canadian Institutes of Health Research (142255), Ministry of Health of the Czech Republic (16-32791A, NU20-04-00393), and Brain & Behavior Research Foundation Young and Independent Investigator Awards. A.Jam. [Oxford] was supported by MRC grant G0500092. P.H. [SWIFT] is supported by a NARSAD grant from the Brain & Behavior Research Foundation (28445) and by a Research Grant from the Novartis Foundation (20A058). R.C.G. [UPENN] received funding through NIH grants 1R01MH117014 and 1R01MH119219. N.J. [ENIGMA] is funded by NIH grant R01MH117601. S.E.M. [ENIGMA] is supported in part by Australian NHMRC APP1172917. J.A.T. [FBIRN, MCIC, COBRE] is supported by NIH grant R01MH121246.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Committee Faculty of Social Sciences, Radboud University Nijmegen, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Additional author added; Updated incorrect reference to a supplementary figure; Minor textual (spelling) corrections; Updated acknowledgments.
Data Availability
This study made use of 46 separate data sets collected around the world, under a variety of different consent procedures and regulatory bodies, during recent decades. Requests to access the data sets will be considered in relation to the relevant consents, rules and regulations, and can be made via the schizophrenia working group of the ENIGMA consortium: http://enigma.ini.usc.edu/ongoing/enigma-asd-working-group/
